Sygnature Chemical Services Ltd., of Nottingham, UK, appointed Paul Clewlow senior vice president of business development, and an executive member of the board

N30 Pharma, of Boulder, Colo., made these appointments to its scientific advisory board: Chairman Joseph Loscalzo, Augustine Choi, Michael Marletta, William Sessa and Joseph Vita...Sigma-Aldrich, of St. Louis, appointed Michael Kanan vice president and corporate controller

Infinity Pharmaceuticals Inc., of Cambridge, Mass., promoted John J. Keilty to vice president of information technology and informatics, and Joseph F. McPherson to vice president of facilities and operations...Microbia, Inc., of Lexington, Mass., appointed Mike Doyle senior vice president and general manager of nutrition ingredients...promoted Stephen DiPalma to executive vice president of business operations and chief financial officer

Hanall Pharmaceuticals, of Seoul, South Korea, appointed Andrew J. Gorman vice president and chief of corporate development...Micromet Inc., of Bethesda, Md., named Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel...Myers, Fla., named Douglas M. VanOort to the board as executive chairman and interim CEO

AVI BioPharma Inc., of Portland, Ore., appointed Stephen B. Shrewsbury chief medical officer and senior vice president of clinical and regulatory affairs Biota Holdings Ltd., of Melbourne, Australia, appointed James Fox as a nonexecutive director and chairman...WuXi PharmaTech, of Shanghai, China, added Stewart Hen and Ning Zhao to its board...XTL Biopharmaceuticals Ltd., of Valley Cottage, N.Y., appointed David Grossman and Boaz Shweiger to its board

Aerovance Inc., of Berkeley, Calif., appointed Babatunde A. Otulana senior vice president and chief medical officer...F2G Ltd., of Manchester, UK, appointed Tony Kennedy chief scientific and development officer...Gentel Biosciences, of Madison, Wis., promoted G. Randall Durnell to executive vice president and chief operating officer

Pluristem Therapeutics Inc., of New York, appointed Frida Grynspan vice president of research and development...PDL BioPharma Inc., of Incline Village, Nev., appointed Christopher L. Stone vice president, general counsel and secretary

MorphoSys AG, of Martinsried, Germany, appointed Ulrich Moebius head of preclinical development and project management...He also will provide strategic direction to Novacta's R&D team and will become chairman of the scientific advisory board...Pharminox Ltd., of Nottingham, UK, appointed Lee Arnold, Adrian Harris and Robert Jackson to its scientific advisory board

Anecova SA, of Geneva, named Barry W. Wilson, Patrick Aebischer and Jeffrey B. Jump to its board...ARCA biopharma Inc., of Broomfield, Colo., appointed Kathryn E. Falberg chief financial officer and chief operating officer...Gene Network Sciences Inc., of Cambridge, Mass., named Michael Gilman, founder and CEO of Stromedix Inc., to its board

New Leaf Venture Partners, of New York, named Srinivas Akkaraju managing director and to lead its West Coast biopharmaceuticals practice...OncoMethylome Sciences, of Liege, Belgium, named Gerard Vaillant to its board, and appointed Gert-Jan Renardel de Lavalette chief operating officer

Sander van Deventer, AMT's chief scientific officer and co-founder of the company, has been named interim CEO...Ligand Pharmaceuticals Inc., of San Diego, named Bruce A. Peacock and Steven J. Burakoff to its board...The company also added former FDA official Marianne Mann and former Merck & Co

The company also added former FDA official Marianne Mann and former Merck & Co...XOMA Ltd., of Berkeley, Calif., appointed Fred Kurland vice president of finance and chief financial officer

and Steve Neben senior director of project and alliance management...Oxigene Inc., of Waltham, Mass., named Nicole Onetto and Eric K. Rowinsky to the board of its subsidiary Symphony ViDA Inc

TyRx Inc., of Monmouth Junction, N.J., appointed William G. Dempsey an independent director. Vitae Pharmaceuticals Inc., of Fort Washington, Pa., promoted Tina Fiumenero to chief financial officer. XOMA Ltd., of Berkeley, Calif., appointed Stephen K. Doberstein vice president of research.

Prognostix Inc., of Cleveland, appointed Jake Orville president and CEO...Thomas Hecht was appointed chairman, and Michael Motschmann will join the board...SuppreMol also named Fritz Melchers and Falk Nimmerjahn to its scientific advisory board

NuPathe Inc., of Conshohocken, Pa., appointed Keith A. Goldan vice president and chief financial officer...PDL BioPharma Inc., of Redwood City, Calif., elected Paul W. Sandman and John P. McLaughlin to its board...Potential Pharmaceuticals, of Louisville, Ky., appointed Johanna M. Seddon and Janet Stoltz Sunness to its scientific advisory board

ImmunoGen Inc., of Waltham, Mass., appointed James J. O'Leary vice president and chief medical officer...Infinity Pharmaceuticals Inc., of Cambridge, Mass., promoted Adelene Q. Perkins president and chief business officer...It also appointed Bruce R. Thaw chairman and named James E. Rothman chairman of the scientific advisory board

The company appointed Craig A. Collard president and CEO and named Alastair McEwan chairman...It also appointed Christopher Codeanne, Michael Enright and Michael Heffernan to the board

Bioheart Inc., of Sunrise, Fla., appointed Matt Fendrich vice president of sales and marketing and named Alan P. Timmins to the board...Biovail Corp., of Toronto, appointed H. Christian Fibiger senior vice president and chief scientific officer of Biovail Laboratories International SRL...BioXcel Corp., of New Haven, Conn., added R. Christopher Seaton, Martha Matteo and Kevin Rakin to its corporate advisory board